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Abstract
Background: Multimorbid patients receiving polypharmacy represent a growing population at high risk for negative
health outcomes. Tailoring is an approach of systematic intervention development taking account of previously
identified determinants of practice. The aim of this study was to assess the effect of a tailored program to improve the
implementation of three important processes of care for this patient group: (a) structured medication counseling
including brown bag reviews, (b) the use of medication lists, and (c) structured medication reviews to reduce
potentially inappropriate medication.
Methods: We conducted a cluster-randomized controlled trial with a follow-up time of 9 months. Participants were
general practitioners (GPs) organized in quality circles and participating in a GP-centered care contract of a German
health insurance. Patients aged >50 years, suffering from at least 3 chronic diseases, receiving more than 4 drugs, and
being at high risk for medication-related events according to the assessment of the treating GP were enrolled. The
tailored program consisted of a workshop for GPs and health care assistants, educational materials and reminders for
patients, and the elaboration of implementation action plans. The primary outcome was the change in the degree of
implementation between baseline and follow-up, measured by a summary score of 10 indicators. The indicators were
based on structured surveys with patients and GPs.
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Results: We analyzed the data of 21 GPs (10 - intervention group, 11 - control group) and 273 patients (130 - intervention
group, 143 - control group). The increase in the degree of implementation was 4.2 percentage points (95% confidence
interval: −0.3, 8.6) higher in the intervention group compared to the control group (p = 0.1). Two of the 10 indicators
were significantly improved in the intervention group: medication counseling (p = 0.017) and brown bag review (p = 0.
012). Secondary outcomes showed an effect on patients’ self-reported use of medication lists when buying drugs in the
pharmacy (p = 0.03).
Conclusions: The tailored program may improve implementation of medication counseling and brown bag review
whereas the use of medication lists and medication reviews did not improve. No effect of the tailored program on the
combined primary outcome could be substantiated. Due to limitations of the study, results have to be interpreted
carefully. The factors facilitating and hindering successful implementation will be examined in a comprehensive process
evaluation.
Trial registration number: ISRCTN34664024, assigned 14/08/2013
Keywords: Multimorbidity, Polypharmacy, Tailoring, Randomized controlled trial, Medication list, Medication review,
Communication, Potentially inappropriate medication
Background
Deficiencies in the care of multimorbid patients with
polypharmacy
Patients suffering from multiple chronic conditions and
being treated with polypharmacy (commonly defined as
permanent intake of more than four drugs) [1] represent a
constantly growing population [2] at high risk for prevent-
able adverse drug reactions (ADR) [3], potentially avoidable
hospital admissions [4] and preventable deaths [5]. Imple-
mentation of evidence-based recommendations for drug
treatment is a challenge in patients with polypharmacy.
Reasons for the high prevalence of preventable negative
health outcomes in this patient group can be found in
different areas of care:
Suboptimal communication between physicians and
patients about medication-related issues in both inpatient
and outpatient settings [6, 7] can cause medication errors
due to inappropriate prescribing, low adherence to, or
wrong application of a prescribed medicine [7, 8].
Prescribing and monitoring errors are common in pri-
mary and hospital care. They may lead to a potentially in-
appropriate medication (PIM), which can be determined by
implicit criteria, such as the Medication Appropriateness
Index (MAI) [9] and explicit criteria, such as the PRISCUS
list, a German adaption of the Beers criteria [10]. Medica-
tion errors according to implicit criteria appear in 5% of all
prescriptions [11]. The PIM prescription rate in the elderly
according to the PRISCUS list in Germany is relatively
stable around 23% with only a small decrease within the
past years [12, 13]. Patients taking PIM are at higher risk
for ADR [14] and hospital admission [15].
Insufficient documentation and exchange of medication-
related information between health care professionals are
a potential cause of prescribing errors and ADR. Since
there is no established electronic system for data exchange
between different health care providers in Germany [16],
to date the written, paper-based medication list of each
individual patient is the most important document for
medication-related information. Yet, deficiencies concern-
ing the quality and availability of medication lists are well
known: In Germany, only 25–50% of patients with poly-
pharmacy have a medication list [17]. Several studies
showed discrepancies between the documented and actu-
ally taken medication in about 75% of the cases [18–20],
with 25% of those discrepancies being considered po-
tentially harmful [21]. Due to lacking standardization,
important information is frequently lacking or in case
of handwritten medication lists not readable [22].
The German health system
Hence, optimal care for multimorbid patients with poly-
pharmacy requires information sharing between multiple
prescribers, input of pharmacological knowledge into
clinical decision making, continuous monitoring, and
counseling of patients. This is particularly challenging
for general practitioners (GPs) who act as main pro-
viders and coordinators of care for most adults with
chronic diseases. Germany has no formal gate-keeping
system in ambulatory care [23], and the GP is not neces-
sarily the central care provider, so that patients’ medica-
tion regimens may be adapted by various physicians
without communicating with a GP. As an attempt to
strengthen the coordinating role of GPs, some German
health insurances offer “GP-centered care contracts
(HzV)” [24]. For some HzV care contracts, regular par-
ticipation in “quality circles” (QC) [25] is obligatory for
GPs. QC comprise educational small group meetings of
GPs of one geographical region and written feedback on
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their individual practice patterns and prescribing beha-
vior on the basis of claims data.
Evidence-based care
An increasing number of studies evaluate strategies to
improve appropriate use of polypharmacy especially in
older patients. Few studies have been done in Germany
and difficulties of providing high-quality evidence in this
field due to methodological challenges have been de-
scribed [26]. So, it is still uncertain which strategies are
most effective [27]. For the study “Implementation of rec-
ommendations for polypharmacy in multimorbid patients
(PomP),” we identified three core recommendations on
drug management in polypharmacy patients from the re-
search literature which are also recommended in a
German guideline for multi-medication in primary
care [28]. They were chosen out of a range of recommenda-
tions, because they focus—as described above—on different
aspects of care with substantiated deficiencies, namely com-
munication, prescribing, and documentation:
Recommendation 1 on communication: structured
medication counseling (SMC): All patients with
polypharmacy and additional risk factors for medication
problems should receive SMC at least once per year.
Beside medication-related information, SMC comprises
a complete inventory of the actually taken medication
(so called “brown bag review”) and the assessment of
patient adherence and possible application problems. A
separate appointment should be planned for SMC [29].
There is evidence that SMC increases patient satisfaction
with health care [30] and adherence and reduce ADR
and hospitalizations [8]. It has been shown that better
physician-patient communication leads to better health
outcomes [31, 32].
Recommendation 2 on documentation: consequent use
of medication lists: All patients with polypharmacy
should take along an updated, complete, and
comprehensible medication list, concordant with the
template of the Drug Commission of the German
Medical Association [14]. There is consensus that
medication lists are an important and useful document
for HCP as well as for patients [33, 34], which is
emphasized by the fact that the patients’ right to
receive a complete medication list has been regularized
by the German E-Health law enacted in 2015
(German Social Security Code 5, §31). It is plausible
that medication lists have a positive influence on
health outcomes.
Recommendation 3 on prescribing: medication reviews
to reduce PIM: Physicians should review the medication
regimens of patients with polypharmacy systematically
with the aid of tools, such as the PRISCUS list [10] or
the MAI [9]. Both tools integrate a substantial body of
knowledge on drug treatment. There is evidence that
systematic medication reviews reduce emergency
department contacts at least in hospital settings [35].
Tailoring
Implementation of evidence-based practice in health
care is often hindered by specific barriers or facilitated
by enablers, also referred to as “determinants of prac-
tice.” Tailored programs are programs explicitly designed
to address such previously identified determinants [36].
This study is part of the “Tailoring Interventions for
Chronic Diseases” (TICD) project [37], during which five
tailored programs have been developed and evaluated in
randomized controlled trials according to a coordinated
research plan [38–42]. The concept of tailoring used in
TICD has been described elsewhere [43].
The aim of the PomP study was to improve the imple-
mentation of three core recommendations in primary
care practices by a tailored program.
Methods
Trial design
The aim of the PomP study was to assess the effectiveness
of a tailored program to improve the implementation of
three core recommendations for medication management
in primary care practices. The primary outcome was
the difference in the degree of implementation between
baseline and follow-up, measured by a summary score
based on 10 indicators. The study design was a cluster-
randomized controlled trial with QCs as unit of
randomization. Follow-up time was 9 months.
Participants and setting
GPs participating in a GP-centered care contract of one
large German health insurance (HzV AOK Baden-
Wuerttemberg) and organized in QCs were recruited. For
this purpose, the moderators of the QCs in one geograph-
ical region in South Germany were contacted. GPs agreeing
to participate received a de-identified list of patients (based
on analyses of insurance claim data) meeting the following
eligibility criteria:
 Patients older than 50 years
 Enrolment into the HzV AOK Baden-Wuerttemberg
care contract
 Prescriptions for more than four different drugs in
at least 2 quarters of the preceding year
 Diagnosis of at least three chronic conditions based
on a previously published diagnosis list with a total
of 42 diagnosis groups [44]
The recruitment of GPs and the data management
of insurance claims data was done by the Institute for
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Applied Quality Improvement and Research in Health
Care (AQUA Institute).
GPs were asked to assess the risk of medication problems
(e.g., due to non-adherence or prior hospitalizations due to
ADR) of these patients and to enroll up to 25 high risk
patients.
Exclusion criteria for GPs were participation in an-
other study focusing on multimorbidity or polypharmacy
during the previous year. Exclusion criteria for patients
were a cognitive or clinical status which hindered active
participation in the study.
Intervention
The tailored program of the PomP study was developed
based on previously identified determinants and strategies.
The “logic model” illustrates the assumed mechanism of
the tailored program (compare Fig. 1) which consisted of
three major elements:
(a)Training and resources for GPs and MAs: During a
four hour workshop for practice teams, GPs and
MAs discussed potential barriers and solutions for
the implementation of the recommendations. MAs
were trained in performing brown bag reviews and
GPs in using online resources and a checklist for
systematic medication reviews. The workshop was
lead by two of the authors (CJ and JS).
(b)Educational material for patients: The practice
teams received posters encouraging patients to take
their medication list with them, brown bags as
reminders to bring their medication packages to the
counseling appointment, and a multilingual “info-tool”
for patients on a tablet PC. The brown bags were used
due to previous evidence [45]; the info-tool was
developed based on a selective literature research and
expert consultation to identify relevant learning targets
for patients related to medication topics.
(c) Implementation action plans: After the workshop
GPs were asked to organize a team meeting and to
elaborate a concept of how to implement the
recommendations in their individual practice.
Details of the tailored program have been described
elsewhere [46].
Control
GPs in the control group were informed about the gen-
eral aim of the study and thus about the three evidence-
based recommendations we intended to implement.
Consequently, they were aware about the “best practice”
and the desired professional behavior. As the enrolment
of patients into the study included the identification of
patients at high risk for ADR, GPs in the control group
were also aware of patients in need for intensified care
in their practice. Beside this, they did not receive any
further instructions or aids for the implementation of
the recommendations.
Fig. 1 Logic model of the PomP intervention
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Primary outcome
The primary outcome was the change in the degree to
which the three core recommendations have been imple-
mented into the primary care practice, measured by a
set of self-developed indicators (Table 1). The decision
for a combined, primary outcome (which had not been
validated before) has its rationale in the logic model of
the intervention (Fig. 1) and the peculiarities of imple-
mentation research: Our aim was to assess whether the
implementation of the recommendations increased, i.e.,
whether the behavior of patients or GPs respectively
changed, whereas it was assumed based on prior evi-
dence that a change of behavior would lead to improved
health outcomes. Since the recommendations comprised
a number of different behavior patterns and since no
validated outcomes reflecting the changes in behavior
were available, we decided to use a range of indicators
reflecting the desired behavior.
The data sources for the indicators were questionnaires
to be completed on a tablet PC in the practice by patients
and GPs at baseline and follow-up. Additionally, we
planned to analyze the medication lists of the practices and
patients. For this purpose, GPs were asked to send the
medication lists they had stored in their practice for each
patient to the study center at baseline and at follow-up.
Furthermore, they were asked to copy and de-identify the
medication lists the patients were carrying with them when
coming to the practice to complete the questionnaires and
send it to the study center. To determine the percentage of
patients carrying a medication list with them, we conducted
an oral survey in each practice: Each patient entering the
practice in a defined time period of 4 h was asked whether
he or she was taking long-term medication and whether he
or she had a medication list with him or her. The responses
were documented anonymously using a tally sheet. Since
this survey was conducted at the practice level, the value
for the indicator 3 (see Table 1) was identical for GPs
working in a group practice.
Secondary outcomes
A set of questionnaires was used to assess medication-
related outcomes at the patient level:
– a self-developed questionnaire assessing the use of
medication lists;
– the German Patient Activation Measure (PAM-13D)
[47] consisting of 13 item with a mean score ranging
from 1–5, higher values reflecting stronger patient
activation
– the Medication Adherence Report Scale (MARS)
[48] consisting of 5 items with a score ranging from
5 to 25, higher values indicating higher adherence
– the specific part of the German Beliefs About
Medicine Questionnaire (BMQ-D) [49] measuring
patients’ beliefs about the particular medication
prescribed for them. It comprises two sub-scales: the
specific necessity scale (SNS) assessing patients’
views on their personal need for their medication
and the specific concerns scale (SCS) assessing
patients concerns towards their medication. Both
Table 1 Indicators of successful implementation of the core recommendations (primary outcome)
Recommendation/implementation objective Indicator Data source
Recommendation 1: SMC incl. brown bag
review was performed at least once
1a Percentage of patients answering the item “Have you had an appointment
for medication counseling with your GP within the last 9 months” in the
affirmative
Patient
questionnaire
1b Percentage of patients answering the item “If yes, have you brought all your
medication packages to this appointment” in the affirmative
Recommendation 2: patients take along
medication lists meeting minimum standards
2a Percentage of medication lists specifying the name of the active substance
of each drug
Medication lists
generated by the
practice
2b Percentage of medication lists specifying the reason for prescription
for each drug
2c Percentage of medication lists specifying the exact dosage for drugs
taken as needed
2d Percentage of medication lists containing instructions for the application
of at least one drug
2e Percentage of medication list with a date not older than 9 months
3 Percentage of patients with long-term medication having a medication
list with them
Oral survey in the
practices
Recommendation 3: GPs review the
medication systematically using tools to
reduce PIM
4a The response scale of the item “Do you use the PRISCUS list” to review the
medication of your patients?” was converted into a percentage value with
always = 100%, frequently = 75%, sometimes = 50%, rarely = 25%, never = 0%
GP questionnaires
4b The response scale of the item “Do you use the MAI” to review the
medication of your patients?” was converted into a percentage value with
always = 100%, frequently = 75%, sometimes = 50%, rarely = 25%, never = 0%
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scales result in a mean score ranging from 1–5, higher
values indication stronger concerns or a stronger
belief in the necessity of the medication respectively.
– the PIM prescription rate based on the PRISCUS list
was measured using insurance claim data (§300
social code book V).
Sample size
As specified in the study protocol [41], we had to use a
proxy (the PIM prescription rate) for the sample size calcu-
lation due to lacking prior knowledge about the primary
outcome used in this trial. A total of 40 practices (20 prac-
tices per group) were assumed to be sufficient to detect a
significant effect of the intervention. Since this sample size
was not reached and regarding other limitations of the trial,
the findings of this trial should be interpreted carefully.
Randomization and allocation concealment
We used QC as unit of randomization. Prior to
randomization, three conditions for the distribution
between intervention and control group were specified:
– The two QCs with the largest number of GPs are
not assigned to the same group.
– The number of enrolled patients is approximately
equal in both groups.
– The number of GPs is approximately equal in both
groups.
Full random sampling was performed using the software
“R,” version 3.0.1 [50]. Seven possible solutions meeting the
conditions listed above were generated. One solution was
selected using a random number function of Microsoft
Excel 2010. Randomization was done by researchers of the
University Hospital Heidelberg not involved into the trial
design after the baseline data collection had been com-
pleted, so that allocation concealment was guaranteed.
Blinding
Due to the nature of the study, GPs and patients could
not be blinded to the intervention.
Statistical methods
The intention-to-treat approach was used for all statistical
analyses, meaning that the analysis population included all
randomized GPs and patients, which were assigned to the
respective treatment group they were originally randomized
to, regardless whether they actually received the respective
intervention or not.
Socio-demographic data on GPs and patients were
analyzed descriptively. Linear regression models were fit
to assess the effect of the tailored program on the
summary score and each individual indicator. The primary
outcome variables at GP level were calculated as the
difference between the baseline and the follow-up assess-
ment. Explanatory variables were treatment group and the
baseline assessment. Generalized estimating equations
were used to adjust for the clustering in practices, with
PCPs on level 1 and GPs on level 2.
Further, secondary outcomes at the patient level were fit-
ted using two-level linear mixed models for continuous
outcomes, which were fitted using the restricted maximum
likelihood method, and two-level generalized mixed models
for binary outcomes using the residual pseudo-likelihood
method, with practices on level 1 and patients on level 2.
All models were adjusted for patient age, gender, highest
number of prescribed drugs in one quarter of the year, and
number of diagnosed chronic diseases. The score difference
between follow-up and baseline was included as dependent
variable in the linear mixed models, while intervention
group and gender were included as fixed factors, alongside
age, highest number of prescribed drugs in one quarter of
the year, number of diagnosed chronic diseases and the out-
come’s baseline value, which were included as fixed covari-
ates. The binary outcome at follow-up was included as
dependent variable in the generalized mixed models, while
intervention group, patient gender, and the binary out-
come’s baseline value were included as fixed factors, and
patient age, highest number of prescribed drugs in one
quarter of the year, and number of diagnosed chronic dis-
eases were included as fixed covariate. For all models, type
III tests for the intervention group effect were performed,
confidence intervals for the effect estimate were calculated,
and the ICC was determined.
All statistical tests were two-sided and a significance
level of alpha = 0.05 was used in the analysis of the pri-
mary outcome. p values pertaining to secondary outcomes
need to be interpreted descriptively. The models were all
fit using PROC GENMOD, PROC MIXED, and PROC
GLIMMIX in SAS 9.4 (SAS Institute Inc., Cary, NC).
Deviations from study protocol
We had to deviate from the study protocol [41] in some
points: The concordance of physicians’ and patients’ medi-
cation list could not be assessed as intended as we received
only very few patient medication lists. The calculated sam-
ple size was not reached, which may have resulted in low
statistical power. To increase the number of patients we
enlarged the included patient population by lowering the
minimum age for inclusion from 65 to 50 years.
Results
Participant flow diagram
Figure 2 shows the participant flow diagram of the trial.
We invited the moderators of 66 QCs to participate in
the study. Twenty-four GPs of 20 practices organized in
11 different QCs agreed to participate. Two GPs were
excluded or dropped out respectively before being
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randomized, because no patients meeting the inclusion
criteria could be identified in the practice or because of
time constraints, respectively. Thus, 22 GPs from 18
practices were available for randomization.
In total, 982 patients meeting the inclusion criteria were
identified using health insurance claims data. Of these,
344 were enrolled into the study after assessment of the
treating GPs. Following the procedure described above, 11
GPs from seven practices organized in five different QCs
and 173 patients were randomized to the intervention
group. Eleven GPs from 11 practices organized in six
different QCs and 171 patients were randomized to the
control group.
In the intervention group, one GP (having enrolled 14
patients) did not participate in the follow-up-assessment
anymore because of time constraints. Another 16 pa-
tients of the intervention group were lost to follow-up.
Reasons specified were patients not being reached by
phone (n = 9), death of patient (n = 1), severe illness of
patients (n = 1), change of GP (n = 1), and withdrawal
from study (n = 4). In the control group, 41 patients
were lost to follow-up. Reasons specified were patients
not being reached by phone (n = 13), patients not com-
ing to appointment (n = 2), change of GP (n = 2), with-
drawal from study (n = 1), death of patient (n = 3),
hospitalization of patient (n = 1), problems with data
transfer (n = 3), and reason not specified (n = 16). Finally,
273 patients were available for the analysis.
Recruitment
Recruitment of practices took place from May 2013 to Au-
gust 2013 and recruitment of patients from September
2013 to December 2013. In the end of January 2014, the
intervention started with the workshop and the hand-
ing over of the resources to the participants. On 15th
of October 2014, the intervention ended with the database
closure for documentation of medication counseling.
Follow-up data collection of patient data started at the
earliest 4 weeks after medication counseling was conducted
and ended on 15th of November 2014. Follow-up data col-
lection of GPs data started after the intervention time was
completed and ended as well on 15th of November 2014.
Baseline data
Table 2 shows the characteristics of the participating GPs
at baseline. The majority of GPs (82%, n = 18) was male
and on average 55 years old. These age and gender pat-
terns deviate slightly from a larger, representative survey
among German GPs, where a higher percentage of female
physicians (35%) was found [51]. There were differences
between the intervention and control group concerning
the structure of the practice and the sex of the GPs. While
the majority of physicians of the intervention group were
organized in group practices, all practices of the control
group were single practices. None of the physicians of the
control group was female. Baseline differences were also
present for patient characteristics (Table 3). Patients of the
control group were by trend older, received more drugs
and suffered from more chronic conditions.
Outcomes
As depicted in Fig. 2, we analyzed the data of 21 GPs
(10 - intervention group, 11 - control group) and 273
patients (130 - intervention group, 143 - control group).
Table 4 shows the results on the primary outcome and
the various indicators on which it is based. The primary
outcome did not differ significantly between the groups.
For two indicators, a change in favor of the intervention
group was observed: Patients in the intervention group
were more likely to have improved receiving structured
medication counseling (p = 0.017) and a brown bag re-
view (p = 0.012) than patients in the control group.
Table 5 shows the results of the analysis on secondary
outcomes at the patient level. No significant effect on
adherence, beliefs in medicine, and patient activation
assessed by validated instruments could be shown, neither
Fig. 2 CONSORT flow diagram of the cluster-randomized trial
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a significant difference in the PIM prescription rate. Con-
cerning the use of medication lists evaluated by a self-
developed patient questionnaire, a significant difference
could be observed in one out of nine items: patients in the
intervention group reported to show their medication list
in the pharmacy more often. There was a tendency that
patients in the intervention group were more likely to
show their medication list at doctor’s appointments.
Harms
This study intended to improve professional and pa-
tient behaviors regarding the organizational processes
in practices. Specifications about the individual treat-
ment of patients were not made. Thus, no additional
harms for patients had to be expected and were not
reported to us.
Discussion
This study examined the effect of a tailored program on
the primary and secondary outcomes, which reflected
the degree of implementation of three recommendations
for patients with multimorbidity and polypharmacy. We
did not observe a significant difference in changes
between groups and the treatment effects for the sin-
gle indicators were heterogenous: Our results suggest
that the implementation of structured medication
counseling and brown bag reviews may have im-
proved in the intervention group and small effects
may be present on patients’ self-reported use of medi-
cation lists when buying drugs in pharmacies. On the
contrary, some of the indicators for medication list
use by GPs had—though not significant—a reverse
tendency indicating a higher adoption of the recom-
mendations in the control group.
Other tailored programs focusing on polypharmacy used
similar strategies than those we selected for our program,
such as academic detailing, education, treatment algo-
rithms, patient information leaflets and paper bags
[45, 52]. We did not include pharmacists, a frequently
used strategy with heterogeneous effects [53], because
this is difficult to implement in German primary care as
collaboration of practices and pharmacists is not well
established. Systematic reviews on interventions to im-
prove polypharmacy often conclude that the effects of the
interventions are conflicting and variable [53–57], so it
remains unclear under which circumstances which strat-
egy effectively improves the use of polypharmacy.
The fact that patients in the intervention group were
more likely to receive medication counseling and a brown
bag review during the previous 9 months than those in the
Table 2 Socio-demographic data of GPs at baseline
Total Intervention Control
Number of GPs 22 11 11
Number of practices 18 7 11
GPs organized in group practices 8 8 0
Mean Age in years (range; SD) 54.9 (44 – 68; 6.8) 54.2 (44–63; 6.0) 55.6 (44–68; 7.8)
Sex male in % (n) 81.8 (18) 63.3 (7) 100 (11)
Mean professional experience as GP in years (range; SD) 22 (8–33; 7.6) 18.8 (8–39; 7.5) 20.1 (11–33; 7.9)
Number of patient contacts per GP per week 222 (120–450; 79.2) 208 (120–450; 94.1) 236 (150–300; 62.2)
Number of MA per practice 4.64 (1–9; SD 2.8) 4.45 (1–9;2.7) 4.82 (1–9; 3.0)
GP general practitioner, SD standard deviation, MA medical assistant
Table 3 Socio-demographic data of patients at baseline
Total Intervention Control p value*
Total number of patients 273 143 130 –
Mean Age [years] 72.2 (SD 8.9) 70.8 (SD 9.1) 73.8 (SD 8.38) 0.006
Sex female % (n) 55.7 (152) 55.9 (80) 55.4 (72) 0.93
Single % (n) 31.7 (85) 30.1 (43) 33.6 (42) 0.54
Living alone % (n) 27.7 (74) 24.6 (35) 31.2 (39) 0.23
Not working % (n) 87.2 (232) 85.9 (122) 88.7 (110) 0.5
Graduation from high school or university % (n) 4.8 (13) 4.9 (7) 4.6 (6) 0.91
Highest number of prescribed drugs in one quarter of the year (range; SD) 7.3 (5–18; 2.6) 7.0 (5–18; 2.6) 7.7 (5–18; 2.6) 0.03
Mean number of diagnosed chronic diseases (range; SD) 5.7 (3–19; 2.8) 5.5 (3–14; 2.2) 6.0 (3–19; 3.2) 0.08
SD standard deviation
*p values are not adjusted for multi-level structure and are based on t test for continuous and chi-squared test for categorical data
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control group suggests that the TI effectively induces
changes on practice organization and related determinants.
However, long-term implementation has to be examined.
There are different possible reasons why the intervention
had no or only a minor effect on the other two recommen-
dations: The baseline performance for some outcomes was
comparatively high, such as 90% of the patients having a
medication list. In other German studies, this rate was
lower between 25 to 50% [17] indicating that there might
have been a selection bias of practices and/or patients,
maybe due to the fact that all practices participated in qual-
ity circles, where pharmaceutical issues are regularly dis-
cussed. The PIM prescription rate of 26–32%, however, was
comparable to larger studies [12, 13]. Furthermore, it may
be possible that important implementation factors were
not successfully addressed by the program, either because
they were not identified or because the selected strategies
were not effective. A comprehensive process evaluation
which was conducted additionally to the main analysis to
examine this issue, showed that fidelity to some of the
intervention components was low and that some import-
ant barriers were not or insufficiently modified and de-
duced suggestions for improvement of the intervention
(Jager C, Steinhauser J, Freund T, Kuse S, Szecsenyi J,
Wensing M. A tailored program to implement recom-
mendations for multimorbid patients with polypharmacy
in primary care practices – process evaluation of a
cluster-randomised trial. Under review in Implementation
Science). Other possible reasons for the low effectiveness
of the trial might be related to limitations of the trial.
Limitations
A limitation of the trial is that the sample size was lower
than planned, which may have led to lack of statistical
power to detect intervention effects. On the other hand,
we had to use a proxy measure for the power calculation
which implies uncertainties regarding this calculation.
Furthermore, we had to use a range of non-validated out-
come parameters since no validated measures for the be-
havior change intended to be induced by the intervention
were available. So it is unclear, whether the used outcome
parameters reliably measure implementation improvement.
The baseline differences in patient characteristics (pa-
tients of the control group were by trend older, received
more drugs and suffered from more chronic diseases)
and the differences in practice structure (all GPs of the
control group worked in single practices while GPs of
the intervention group worked in group practices) might
be relevant determinants for the implementation of
guideline recommendations, especially since the ICC
was extraordinarily high for several outcomes, suggest-
ing that patient outcomes strongly depended on the
practice with a high variance between practices.
Although we reduced the minimum age for inclusion
to 50 years, the patterns for age, sex, family status, and
living arrangements were similar to those of a German
representative epidemiological study on multimorbidity
[58]. Previous research found that 25% of patients suffer-
ing from at least 6 chronic conditions are younger than
50 years [59]. This indicates that polypharmacy is not
only a challenge in elderly patients but that also younger
patients might profit from intensified care. This should
be taken into account in further research projects.
Given the limitations of the study, the findings of the
trial need to be interpreted carefully in an explorative
manner. However, we believe that the information
provided by the study is nevertheless useful for other
researchers in the field of medication management—a
Table 4 Results on the various indicators and the summary outcome
Indicatora Baseline T0 Follow-up T1 Treatment effect p value
Control Intervention Control Intervention
MEAN % (SD) MEAN % (SD) MEAN % (SD) MEAN % (SD) Estimate (95% CI)
1a 61.8 (27.6) 59.1 (28.6) 49.0 (30.0) 82.7 (20.4) 34.2 (12.4, 55.9) 0.017
1b 43.4 (36.0) 45.7 (37.8) 20.9 (20.9) 59.2 (33.9) 38.8 (15.0, 62.7) 0.012
2a 0 (0) 0.01 (0.02) 4.0 (7.5) 2.6 (6.3) −3.4 (−8.0, 1.2) 0.18
2b 0 (0) 0.01 (0.02) 0 (0) 1.9 (5.6) 2.1 (−1.4, 5.5) 0.28
2c 1.4 (0.4) 1.7 (0.3) 48.4 (36.7) 25.0 (35.4) −23.2 (−63.2, 16.8) 0.24
2d 27.4 (43.8) 25.6 (33.3) 31.2 (47.6) 8.2 (22.1) −21.5 (−50.9, 8.0) 0.18
2e 70.9 (35.0) 55.3 (41.1) 93.9 (12.0) 92.7 (9.2) 0.1 (−9.2, 9.3) 0.99
3 10.9 (5.9) 13.7 (4.7) 20.8 (5.1) 14.5 (19.3) −8.1 (−15.0, 1.2) 0.08
4a 25.0 (29.6) 15.0 (26.9) 20.5 (18.8) 22.5 (18.5) 5.6 (−5.6, 16.7) 0.35
4b 0 (0) 10.0 (24.2) 2.3 (7.5) 10.0 (21.1) 2.5 (−7.5, 12.4) 0.62
Primary outcome 24.1 (6.7) 22.8 (13.0) 27.9 (6.5) 31.5 (8.0) 4.2 (−0.3, 8.6) 0.10
SD standard deviation
aFor explanation of the indicators, see Table 1
Jäger et al. Implementation Science  (2017) 12:8 Page 9 of 13
Ta
b
le
5
Re
su
lts
of
th
e
se
co
nd
ar
y
ou
tc
om
es
Va
lid
at
ed
in
st
ru
m
en
ts
Ba
se
lin
e
T0
Fo
llo
w
-u
p
T1
Es
tim
at
e
(9
5%
C
I)
p
va
lu
e
IC
C
C
on
tr
ol
In
te
rv
en
tio
n
C
on
tr
ol
In
te
rv
en
tio
n
M
EA
N
(S
D
)
M
EA
N
(S
D
)
M
EA
N
(S
D
)
M
EA
N
(S
D
)
M
A
RS
sc
or
e
(a
dh
er
en
ce
)
23
.3
(2
.3
)
23
.3
(3
.7
)
23
.3
(2
.6
)
22
.3
(3
.3
)
−
1.
2
(−
2.
8,
0.
3)
0.
11
0.
18
PA
M
sc
or
e
(p
at
ie
nt
ac
tiv
at
io
n)
3.
3
(0
.4
)
3.
3
(0
.5
)
3.
3
(0
.5
)
3.
3
(0
.5
)
0.
1
(−
0.
1,
0.
2)
0.
48
0.
08
BM
Q
ne
ce
ss
ity
sc
or
e
4.
5
(0
.5
)
4.
2
(0
.6
)
3.
3
(0
.5
)
3.
3
(0
.6
)
−
0.
1
(−
0.
4,
0.
3)
0.
68
0.
20
BM
Q
co
nc
er
ns
sc
or
e
2.
5
(0
.9
)
2.
5
(0
.9
)
1.
4
(0
.8
)
1.
8
(0
.9
)
0.
2
(−
0.
2,
0.
6)
0.
24
0.
11
N
um
be
r
of
PI
M
pr
es
cr
ip
tio
ns
pe
r
ye
ar
[ra
ng
e]
0.
9
(1
.8
)
[0
–9
]
0.
8
(1
.8
)
[0
–1
0]
1.
0
(1
.9
)
[0
–9
]
0.
8
(1
.8
)
[0
–1
1]
−
0.
1
(−
0.
4,
0.
2)
0.
37
<
0.
01
N
um
be
r
of
pa
tie
nt
s
w
ith
≥
1
PI
M
pr
es
cr
ip
tio
n
pe
r
ye
ar
32
.3
%
(n
=
42
)
27
.7
%
(n
=
39
)
30
.0
%
(n
=
39
)
26
.2
%
(n
=
37
)
0.
9
(0
.4
,2
.0
)
0.
81
0.
02
Se
lf-
de
ve
lo
pe
d
su
rv
ey
(it
em
s
w
ith
bi
na
ry
re
sp
on
se
ca
te
go
rie
s)
a
C
on
tr
ol
In
te
rv
en
tio
n
C
on
tr
ol
In
te
rv
en
tio
n
Es
tim
at
e
(9
5%
C
I)
p
va
lu
e
IC
C
%
(n
)
%
(n
)
%
(n
)
%
(n
)
D
o
yo
u
ha
ve
a
w
rit
te
n
m
ed
ic
at
io
n
lis
t?
91
.5
(1
18
)
91
.6
(1
31
)
93
.0
(1
19
)
95
.8
(1
37
)
1.
5
(0
.2
–1
2.
3)
0.
69
0.
36
Iu
se
m
y
m
ed
ic
at
io
n
lis
t
as
a
re
m
in
de
r
53
.4
(6
2)
60
.0
(7
8)
61
.0
(7
2)
65
.0
(8
9)
1.
0
(0
.2
–4
.8
)
0.
98
0.
32
Iu
su
al
ly
sh
ow
m
y
m
ed
ic
at
io
n
lis
t
at
do
ct
or
’s
ap
po
in
tm
en
ts
19
.8
(2
3)
42
.7
(5
6)
22
.0
(2
6)
46
.0
(6
3)
4.
7
(0
.8
–2
9.
6)
0.
09
0.
39
Iu
su
al
ly
sh
ow
m
y
m
ed
ic
at
io
n
lis
t
in
th
e
ph
ar
m
ac
y
0.
0
(0
)
7.
7
(1
0)
5.
1
(6
)
28
.5
(3
9)
12
.9
(1
.4
–1
17
.7
)
0.
03
0.
42
Iu
se
m
y
m
ed
ic
at
io
n
lis
t
w
he
n
ta
ki
ng
m
y
m
ed
ic
am
en
ts
55
.2
(6
4)
45
.4
(5
9)
63
.6
(4
8.
5)
59
.1
(8
1)
0.
6
(0
.2
–2
.1
)
0.
43
0.
20
Se
lf-
de
ve
lo
pe
d
su
rv
ey
(it
em
s
w
ith
fiv
e-
po
in
t
Li
ke
rt
re
sp
on
se
sc
al
e)
b
C
on
tr
ol
In
te
rv
en
tio
n
C
on
tr
ol
In
te
rv
en
tio
n
Es
tim
at
e
(9
5%
C
I)
p
va
lu
e
IC
C
%
(n
)
%
(n
)
%
(n
)
%
(n
)
D
o
yo
u
fin
d
yo
ur
m
ed
ic
at
io
n
lis
t
co
m
pr
eh
en
si
bl
e?
96
.6
(1
14
)
93
.1
(1
22
)
89
.8
(1
06
)
90
.9
(1
30
)
1.
3
(0
.2
–1
0.
9)
0.
77
0.
41
D
o
yo
u
di
sp
os
e
of
th
e
ol
d
m
ed
ic
at
io
n
lis
t
af
te
r
re
ce
iv
in
g
a
ne
w
on
e?
78
.0
(9
2)
69
.5
(8
9)
77
.1
(9
1)
75
.9
(1
07
)
0.
8
(0
.3
–1
.8
)
0.
51
0.
04
D
o
yo
u
ca
rr
y
yo
ur
m
ed
ic
at
io
n
lis
t
w
ith
yo
u
(e
.g
.,
in
yo
ur
pu
rs
e?
)
33
.9
(4
0)
36
.9
(4
8)
37
.3
(4
4)
48
.3
(6
9)
1.
3
(0
.4
–4
.8
)
0.
64
0.
21
D
o
yo
u
no
te
do
w
n
on
yo
ur
m
ed
ic
at
io
n
lis
t
if
yo
u
ta
ke
a
m
ed
ic
am
en
t
w
hi
ch
yo
u
ha
ve
bo
ug
ht
yo
ur
se
lf?
13
.8
(1
6)
18
.3
(2
4)
16
.9
(2
0)
25
.0
(3
5)
1.
3
(0
.4
–5
.0
)
0.
65
0.
19
IC
C
in
tr
ac
lu
st
er
co
rr
el
at
io
n
co
ef
fic
ie
nt
SD
st
an
da
rd
de
vi
at
io
n
CI
co
nf
id
en
ce
in
te
rv
al
n
nu
m
be
r
a N
um
be
rs
sh
ow
th
e
pe
rc
en
ta
ge
of
re
sp
on
de
nt
s
an
sw
er
in
g
th
e
ite
m
af
fir
m
at
iv
el
y
b
N
um
be
rs
sh
ow
th
e
pe
rc
en
ta
ge
of
re
sp
on
de
nt
s
an
sw
er
in
g
th
e
ite
m
s
w
ith
“a
lw
ay
s”
or
“f
re
qu
en
tly
”
Jäger et al. Implementation Science  (2017) 12:8 Page 10 of 13
relatively young research field in Germany which is receiv-
ing more and more scientific and political attention.
Conclusions
This study examined a tailored program intending to
improve the implementation of three evidence-based
recommendations for the management of multimorbid
patients with polypharmacy in primary care. No effect
on the combined primary outcome could be substanti-
ated. Yet, the results suggest that the program may lead
to improved implementation of structured medication
counseling and brown bag reviews, while only a mar-
ginal effect on the use of medication lists and no effect
on the use of tools for medication reviews could be
observed. Due to limitations of the trial, the results
should be interpreted in an explorative manner. The fac-
tors facilitating and hindering successful implementation
are examined separately in a comprehensive process
evaluation.
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